Diffuse optical tomography of the breast: preliminary findings of a new prototype and comparison with magnetic resonance imaging by Stephanie M. W. Y. van de Ven et al.
Eur Radiol (2009) 19: 1108–1113
DOI 10.1007/s00330-008-1268-3 BREAST
Stephanie M. W. Y. van de Ven
Sjoerd G. Elias
Andrea J. Wiethoff









Martin B. van der Mark
Peter Luijten
Willem P. Th. M. Mali
Received: 4 July 2008
Revised: 14 November 2008
Accepted: 27 November 2008
Published online: 10 January 2009
# The Author(s) 2008.
This article is published with open access at
Springerlink.com
Diffuse optical tomography of the breast:
preliminary findings of a new prototype
and comparison with magnetic resonance
imaging
Abstract This paper presents an
evaluation of a prototype diffuse op-
tical tomography (DOT) system. Se-
venteen women with 18 breast lesions
(10 invasive carcinomas, 2 fibroade-
nomas, and 6 benign cysts; diameters
13–54 mm) were evaluated with DOT
and magnetic resonance imaging
(MRI). A substantial fraction of the
original 36 recruited patients could not
be examined using this prototype due
to technical problems. A region of
interest (ROI) was drawn at the lesion
position as derived from MRI and at
the mirror image site in the contralat-
eral healthy breast. ROIs were as-
sessed quantitatively and qualitatively
by two observers independently in two
separate readings. Intra- and interob-
server agreements were calculated
using kappa statistics (k) and intraclass
correlation coefficients (ICCs). Dis-
criminatory values for presence of
malignancy were determined by re-
ceiver operating characteristic (ROC)
analyses. Intraobserver agreements
were excellent (k 0.88 and 0.88; ICC
0.978 and 0.987), interobserver
agreements were good to excellent (k
0.77–0.95; ICC 0.96–0.98). Discrimi-
natory values for presence of malig-
nancy were 0.92–0.93 and 0.97–0.99
for quantitative and qualitative ROC
analysis, respectively. This DOT
system has the potential to discrimi-
nate malignant from benign breast
tissue in a reproducible qualitative and
quantitative manner. Important tech-
nical improvements are required be-
fore this technique is ready for clinical
application.
Keywords Optical tomography .
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Introduction
Diffuse optical tomography (DOT) employs light in the
near-infrared (NIR) spectrum, where light absorption is
minimal (650–1,000 nm), to assess the optical properties of
tissue [1]. Information on the composition of the breast
tissue, i.e., relative concentrations of oxy- and deoxyhe-
moglobin, water, and lipid can be obtained by combining
images acquired at different wavelengths (spectroscopic
imaging). Hemoglobin concentration in a malignant tumor
is directly related to angiogenesis [2], and proportions of
oxy- and deoxyhemoglobin change as a result of its
metabolism [3]. By using multiple wavelengths to measure
concentrations of the main chromophores in the breast,
discrimination between benign and malignant tissue may
be possible with DOT. This technique could potentially
have added value to currently used breast imaging
modalities, i.e., mammography, ultrasound, and dynamic
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contrast-enhanced magnetic resonance imaging (DCE-
MRI), which all have drawbacks regarding sensitivity
and specificity in the diagnosis, early detection, and
treatment monitoring of breast cancer [4–7].
Since optical breast imaging is still in its infancy with
several techniques being explored [8], thorough system
evaluation and validation is essential. We used MRI as a
benchmark for the first diagnostic evaluation of our new
prototype since it provides three-dimensional data and
excellent soft tissue contrast. We initiated the evaluation
under optimal settings in a small patient group by (1)
investigating optical properties of different types of breast
lesions; (2) assessing the potential to discriminate between
benign and malignant tissue with a known lesion position;
and (3) assessing the effect of intra- and interobserver
variability on the obtained results.
Methods
Patients
Seventeen women (mean age 54, range 22–85) diagnosed
with one or more breast lesion(s) 13 to 54 mm in diameter
were prospectively included between August 2006 and
September 2007 from the University Medical Center
Utrecht and the Diakonessenhuis Utrecht, The Nether-
lands. Patients were referred either by their family doctor or
breast surgeon for diagnostic purposes, or via the screening
program for further workup. Patients were asked to
participate in our study if a BI-RADS (Breast Imaging
Reporting and Data System) 2–5 lesion was diagnosed on
mammography/ultrasound, and if needle aspiration was not
performed before the other study procedures could be
executed, since this could influence the optical images. All
patients underwent optical imaging and DCE-MRI. In total,
36 patients were recruited consecutively; however, 19 of
Fig. 1 Diffuse optical tomography prototype (Philips Healthcare,
Best, The Netherlands)
Fig. 2 Examples of ROIs on
DOT images compared with
MRI. a Patient is a 60-year-old
woman with lesion in the right
breast; BI-RADS category 2 on
MRI (left image T2-weighted
MRI with fat suppression); vis-
ibility score −4 on DOT (right
image); final diagnosis, benign
cyst. b Patient is a 56-year-old
woman with lesion in the right
breast; BI-RADS category 5 on
MRI (left image DCE-MRI);
visibility score +4 on DOT
(right image); final diagnosis,
invasive ductal carcinoma
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these were excluded due to (a) technical limitations of our
DOT system, i.e., leakage of matching fluid from the
system (6 patients) and the inability to measure lesions
located close to the patient’s chest wall due to the geometry
of the cup (8 patients); and (b) the inability to undergo
DCE-MRI for reason of claustrophobia (3 patients) and
physical limitations (2 patients did not fit in the MRI bore).
The protocol was approved by the ethics committee of the
University Medical Center Utrecht, and written informed
consent was obtained from all patients.
Optical imaging
DOT was performed on a Philips diffuse optical
tomography system (Philips Healthcare, Best, The
Netherlands). A patient was placed in the prone position
on the system bed with her breast suspended in a cup on
which 507 optical fibers are mounted (Fig. 1). The 253
source fibers are connected to four continuous wave
solid-state lasers (wavelengths 690, 730, 780, and
850 nm) and interleaved with 254 detector fibers. The
cup was filled with a matching fluid, which has optical
properties similar to an average breast, to enable a
stable optical coupling between fibers and breast, and to
eliminate optical shortcuts around the breast. During
imaging, the breast was sequentially illuminated from all
source positions and light emanating from the breast was
detected in parallel for each source position. Acquisition
duration was approximately 1 min per wavelength per
breast, leading to a total examination time of approxi-
mately 10 min per patient. After optical data acquisition,
three-dimensional absorption images were reconstructed
for each wavelength by using a linear reconstruction
algorithm based on the Rytov approximation [9].
MRI
Dynamic contrast-enhanced breast MRI was performed on
a 3.0-T clinical MR system (3.0T Achieva, Philips
Healthcare, Best, The Netherlands). Patients were placed
in prone position on a dedicated four-element SENSE-
compatible phased-array bilateral breast coil (MRI devices,
Würzburg, Germany) utilized for simultaneous imaging of
both breasts. The MR protocol included an axial high-
resolution T1-weighted fast gradient echo (HR-T1FFE) fat-
suppressed series (TE/TR 1.7/4.5 ms; inversion delay
SPAIR 130 ms; flip angle 10°; FOV 340×340 mm2,
acquired voxel size 0.66×0.66×1.6 mm3, reconstructed
voxel size 0.66×0.66×0.80 mm3), followed by an axial
T2-weighted fat-suppressed series (TE/TR 120/9,022 ms;
inversion delay SPAIR 125 ms; flip angle 90°; FOV 340×
340 mm2, acquired voxel size 1.01×1.31×2.0 mm3,
reconstructed voxel size 0.66×0.66×2.00 mm3). Finally,
dynamic contrast-enhanced fat-suppressed T1-weighted
images were acquired (TE/TR 1.3/3.4 ms; flip angle 10°;
FOV 320 mm×320 mm, acquired voxel size 0.91 mm×
0.91 mm×2.00 mm, reconstructed voxel size 0.83 mm×
0.83 mm×1.00 mm, temporal resolution 50 s per dynamic
acquisition) with a total of six dynamic acquisitions, one
obtained before, and five obtained 0, 60, 120, 180, and
240 s after administration of a bolus injection of 0.1 mmol/
kg gadolinium-based contrast agent (Magnevist, Schering,
Berlin, Germany) followed by a 20-ml saline flush at an
injection rate of 3 ml/s with an automatic injector.
Image interpretation
MR images were interpreted by two breast radiologists
with more than 10 years of experience and were used
to derive the location of the lesions. A region of
interest (ROI) was drawn at the lesion site location for
all four optical absorption images (e.g., see Fig. 2). For
comparison, a similar ROI was drawn at the mirror
image lesion site location of the contralateral breast,
where no lesion was found. The visibility of the lesions on
Table 1 Median (range) of quantitative score according to lesion presence and lesion type
Wavelength (nm) Lesion type No lesion (n=18)
Malignant (n=10) Fibroadenoma (n = 2) Cyst (n=6)
690 3.03 (1.91–3.40) 1.75 (1.36–2.14) 0.23 (0.10–0.73) 1.39 (0.32–3.21)
730 2.94 (1.74–6.31) 1.50 (1.01–1.98) 0.17 (0.07–0.75) 1.34 (0.29–3.18)
780 2.57 (1.54–3.22) 1.36 (1.13–1.58) 0.13 (0.08–0.82) 1.29 (0.72–2.58)
850 2.15 (1.27–2.55) 1.30 (1.24–1.35) 0.13 (0.08–0.89) 1.16 (0.71–2.34)
Table 2 Discriminatory value of quantitative score for presence of
malignancy (n=10; total of 36 breasts)







DOT was assessed both quantitatively and qualitatively.
Quantitative values were computed from the volume
images of the optical absorption coefficient obtained from
the DOT system. The mean absorption coefficient of the
ROI was divided by the mean absorption of the back-
ground, which included the rest of the breast on that slice
except for the lesion (the quantitative score). Qualitative
scores for contrast relative to background were given
independently by two readers for every ROI, on a scale
from −4 to 4, where: 0=no visibility; 1=slight heteroge-
neity seen at the site of the known lesion; 2=moderate
contrast, but less/more than other structures, seen at the
site of the known lesion; 3=contrast at the known lesion
site comparable to that of other structures; 4=major
contrast at the known lesion site; a minus sign was used if
the signal at the ROI was lower than the background, and a
plus sign when it was higher. To learn how to score the
images, readers were shown an example set of classified
images (not from the study population) before they started
the scoring process. All images were made anonymously,
placed in random order, and scored by two readers
separately, without knowledge from other examinations.
Images were scored again after 3 months in a second
independent reading by the two investigators.
The reference standard for final diagnosis of the solid
lesions was histopathology, whereas for the benign cysts
and the healthy contralateral breast (mirror image) the
reference standard was MRI. The patients diagnosed with
benign cysts received a follow-up mammography and
ultrasound after 6 months.
Statistics
Intra- and interobserver agreements between the two
readers were calculated using kappa statistics and intraclass
correlation coefficients [10]. Discriminatory values for
presence of malignancy were determined by receiver
operating characteristic (ROC) analyses. Cancer detection
rates were calculated using a qualitative score of ≥ 2 as a
cutoff. The package SPSS 15.0 (SPSS Inc., Chicago, IL,
USA) was used for all statistical computations.
Results
Seventeen patients (mean age 54, range 22–85) with 18
breast lesions underwent optical imaging and DCE-MRI.
Of the 18 lesions, 10 lesions were diagnosed as malignant
by histopathology after surgery (9 invasive ductal carci-
nomas and 1 invasive lobular carcinoma; final BI-RADS
score was BI-RADS 5 in 7 lesions and BI-RADS 4 in 3
lesions) with a median diameter of 23.5 mm (range 13–
54 mm); 2 lesions were confirmed to be benign
fibroadenomas (final BI-RADS score 3) by large core
needle biopsy, with diameters of 13 and 24 mm; and 6
lesions were diagnosed as benign cysts (final BI-RADS
score 2) by ultrasound and MRI, with a median diameter of
28.5 mm (range 20–40 mm); the 23 mirror image regions
of the contralateral breasts appeared as normal breast tissue
without lesions on DCE-MRI.
Quantitative scores (ROI-to-background ratios) are
shown in Table 1. Scores for malignant lesions were
higher (2.15–3.03) than those for fibroadenomas (1.30–
1.75), cysts (0.13–0.23), and the contralateral normal
breast (1.16–1.39). Discriminatory values of quantitative
scores for presence of malignancy are shown in Table 2,
with areas under the ROC curves of 0.92–0.93.
For intraobserver agreements, intraclass correlation
coefficients and kappa statistics were excellent (Table 3).
Intraclass correlation coefficients were excellent and kappa
statistics were good to excellent for the interobserver
Table 4 Interobserver agreement for visibility scores (total of 36 breasts, four wavelengths per breast)
Wavelength (nm) Intraclass correlation coefficienta (95% confidence interval) Kappa statisticb (95% confidence interval)
690 0.96 (0.92–0.98) 0.77 (0.58–0.96)
730 0.98 (0.95–0.99) 0.95 (0.85–1.00)
780 0.96 (0.92–0.98) 0.80 (0.61–0.99)
850 0.97 (0.95–0.99) 0.89 (0.74–1.00)
aOriginal visibility scores; one-way random effects model where people effects are random (single measures)
bVisibility scores recoded into categories (<−1, −1 to 1, >1)
Table 3 Intraobserver agreement for visibility scores (total of 36 breasts, four wavelengths per breast)
Wavelength Intraclass correlation coefficienta (95% confidence interval) Kappa statisticb (95% confidence interval)
Observer 1 Observer 2 Observer 1 Observer 2
All 0.978 (0.970–0.983) 0.987 (0.982–0.990) 0.88 (0.82–0.94) 0.88 (0.82–0.94)
aOriginal visibility scores; one-way random effects model where people effects are random (single measures)
bVisibility scores recoded into categories (<−1, −1 to 1, >1)
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agreement (Table 4). Qualitative visibility scores are shown
in Table 5. Scores for malignant lesions were higher (2–4)
than for fibroadenomas (0–2), cysts (−4), and the contra-
lateral normal breast (0). Table 6 shows the discriminatory
values of qualitative scores for presence of malignancy for
both observers (equal results), with areas under the ROC
curves of 0.97–0.99. Cancer detection rates for the four
wavelengths (690, 730, 780, and 850 nm, respectively)
were 70%, 80%, 80%, and 70% for observer 1; and 60%,
70%, 70%, and 60% for observer 2. Between 0% and 22%
false positive results were found per wavelength for both
observers.
Discussion
This study describes the first diagnostic evaluation under
optimal settings of a new prototype DOT system with MRI
as a benchmark in patients with breast lesions. Using a
known lesion position, malignant lesions could be
discriminated from benign tissue both quantitatively and
qualitatively, mainly owing to higher hemoglobin contents
causing more light absorption. Intra- and interobserver
agreement were good to excellent, indicating a reproduci-
ble method.
Our results are in agreement with previously published
studies using different techniques [11–26]. Detection rates
ranging from 0.04 to 1.00 were reported, irrespective of
lesion classification (benign/malignant). Cancer detection
rates in our study were between 60% and 80% for each
wavelength separately, using a cutoff value of 2; detection
rates and false positive results can likely be improved when
combining information from four different wavelengths in
one model (spectroscopic imaging). Similar to other
research groups, we used knowledge of lesion localization
from a reference standard (MRI in this instance) for the
evaluation of the optical data. This approach in image
interpretation may have resulted in limited false positive
findings with consequent overestimation of the ROC
analyses. However, the areas under the ROC curves justify
further evaluation and development of the technique.
As this study represents the first evaluation of a new
prototype for malignant lesion detection conclusions
should be drawn with care due to important limitations of
the system. In addition, because the sample size of the
study was small and the study group was selective,
obtained results cannot be extrapolated directly to a clinical
diagnostic or screening setting. Technical limitations of the
DOT system resulted in the exclusion of 14 of the 36
patients for image analysis. These major limitations
comprised the leakage of matching fluid from the system
resulting in large artifacts, and the limitation in the current
geometry of the system to measure lesions located close to
the patient’s chest wall. Most likely, these lesions were
physically located too far above the upper optical fibers in
the cup to influence the light pathways during optical
imaging. Improvement in cup shape is feasible and should
be realized to visualize these lesions. A limitation of DOT
in general is the poor spatial resolution [1, 16]. This results
in a lower signal-to-noise ratio and limited detection of
very small lesions. Median diameters of the included
lesions in our study were relatively long; the smallest
detected lesion by DOT in our study sample was 13 mm,
and may therefore not be representative for the routine
clinical and screening situation. Further studies including
more patients with smaller lesions will be performed to get
a more realistic estimate of the system’s diagnostic value. A
molecular imaging approach using certain fluorescent
probes may vastly improve signal-to-noise ratios by signal
amplification [27]. Target-specific fluorescent probes for
optical imaging have already been used successfully in
animal experiments [28–30].
In conclusion, this novel DOTsystem has the potential to
discriminate malignant from benign breast tissue by
assessing optical properties of the tissue in a reproducible
Table 6 Discriminatory value of visibility score for presence of
malignancy (n=10; total of 36 breasts)
Wavelength
(nm)
Area under ROC curve (95% confidence interval)





Table 5 Median (range) visibility score according to lesion presence and lesion type
Wavelength (nm) Lesion type No lesion (n=18)
Malignant (n=10) Fibroadenoma (n=2) Cyst (n=6)
Observer 1 Observer 2 Observer 1 Observer 2 Observer 1 Observer 2 Observer 1 Observer 2
690 2 (0–4) 2 (0–4) 1 (0–2) 2 (0–4) −4 (−4 to −1) −4 (−4 to −1) 0 (−2 to 2) 0 (0–3)
730 2 (0–4) 2 (0–4) 1 (1–1) 0 (0–0) −4 (−4 to 0) −4 (−4 to 0) 0 (0–2) 0 (0–3)
780 2 (0–4) 4 (0–4) 0 (0–0) 0 (0–0) −4 (−4 to −1) −4 (−4 to 0) 0 (−1 to 1) 0 (−2 to 2)
850 2 (0–4) 2 (0–4) 0 (0–0) 0 (0–0) −4 (−4 to 0) −4 (−4 to 0) 0 (−1 to 1) 0 (0–2)
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quantitative and qualitative way. Important technical
improvements are required before this technique will be
ready for use in clinical practice.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
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